CTI 118
Alternative Names: anti-COVID-19 therapeutics - Boston University School of Medicine/Cellics Therapeutics/University of California, San Diego; CTI-118; Nanosponge based therapeutics - Boston University School of Medicine/University of California, San DiegoLatest Information Update: 28 Jul 2024
At a glance
- Originator Boston University School of Medicine; University of California, San Diego
- Class Anti-inflammatories; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
- 17 Jun 2020 Early research in COVID-2019 infections in USA (unspecified route), before June 2020
- 17 Jun 2020 Boston University School of Medicine and University of California, San Diego along with Cellics Therapeutics plans further validation studies for COVID-19 infections in USA